参考文献/References:
[1] 王欣怡.甲状腺癌的相关基因BRAF、RET、RAS研究新进展[J].重庆医学,2018,47(36):4631-4634.DOI:10.3969/j.issn.1671-8348.
[2] Bible KC,Kebebew E,Brierley J,et al.2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer[J].Thyroid,2021,31(3):337-386.DOI:10.1089/thy.2020.0944.
[3] Iyer PC,Dadu R,Gule-Monroe M,et al.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J].J Immunother Cancer,2018,6(1):68.DOI:10.1186/s40425-018-0378-y.
[4] Savvides P,Nagaiah G,Lavertu P,et al.Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J].Thyroid,2013,23(5):600-604.DOI:10.1089/thy.2012.0103.
[5] Sherman EJ,Dunn LA,Ho AL,et al.Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer[J].Cancer,2017,123(21):4114-4121.DOI:10.1002/cncr.30861.
[6] Chen G,Nicula D,Renko K,et al.Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells[J].Oncol Rep,2015,33(4):1994-2000.DOI:10.3892/or.2015.3805.
[7] Wirth LJ,Brose MS,Sherman EJ,et al.Open-label,single-arm,multicenter,phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer[J].J Clin Oncol,2021,39(21):2359-2366.DOI:10.1200/JCO.20.03093.
[8] Su X,Liu J,Zhang H,et al.Lenvatinib promotes the antitumor effect of doxorubicin in anaplastic thyroid cancer[J].Onco Targets Ther,2020,13:11183-11192.DOI:10.2147/OTT.S278349.
[9] Ruan X,Shi X,Dong Q,et al.Antitumor effects of anlotinib in thyroid cancer.[J].Endocr Relat Cancer,2019,26(1):153-164.DOI:10.1530/ERC-17-0558.
[10] Liang J,Jin Z,Kuang J,et al.The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis[J].Br J Cancer,2021,125(3):390-401.DOI:10.1038/s41416-021-01340-x.
[11] Zhang X,Wang C,Lin Y.Pilot dose comparison of apatinib in chinese patients with progressive radioiodine-refractory differentiated thyroid cancer[J].J Clin Endocrinol Metab,2018,103(10):3640-3646.DOI:10.1210/jc.2018-00381.
[12] Feng H,Cheng X,Kuang J,et al.Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J].Cell Death Dis,2018,9(10):1030.DOI:10.1038/s41419-018-1054-3.
[13] Wang Y,Hu Z,Ma W,et al.Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer[J].Invest New Drugs,2021,39(3):764-774.DOI:10.1007/s10637-020-01024-y.
[14] Subbiah V,Kreitman RJ,Wainberg ZA,et al.Dabrafenib plus trametinib in patients with BRAFV600E-mutant anaplastic thyroid cancer:updated analysis from the phase II ROAR basket study[J].Ann Oncol,2022,33(4):406-415.DOI:10.1016/j.annonc.2021.12.014.
[15] Tan J,Liu R,Zhu G,et al.TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors:achilles Heel[J].Proc Natl Acad Sci U S A,2020,117(27):15846-15851.DOI:10.1073/pnas.2004707117.
[16] Wirth LJ,Sherman E,Robinson B,et al.Efficacy of selpercatinib in RET-altered thyroid cancers[J].N Engl J Med,2020,383(9):825-835.DOI:10.1056/NEJMoa2005651.
[17] Fallahi P,Ferrari SM,La Motta C,et al.CLM29 and CLM24,pyrazolopyrimidine derivatives,have antitumoral activity in vitro in anaplastic thyroid cancer,with or without BRAF mutation[J].Endocrine,2016,53(1):136-144.DOI:10.1007/s12020-015-0717-4.
[18] Cabanillas ME,Drilon A,Farago AF,et al.1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer[J].Ann Oncol,2020,31:S1026-S1033.DOI:10.1016/j.annonc.2020.08.1404.
[19] Brauner E,Gunda V,Vanden Borre P,et al.Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J].Oncotarget,2016,7(13):17194-17211.DOI:10.18632/oncotarget.7839.
[20] Dierks C,Seufert J,Aumann K,et al.Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma[J].Thyroid,2021,31(7):1076-1085.DOI:10.1089/thy.2020.0322.
相似文献/References:
[1]辅容,卢琳,龚凤英,等.库欣病的分子机制及靶向药物[J].国际内分泌代谢杂志,2016,36(06):400.[doi:10.3760/cma.j.issn.1673-4157.2016.06.11]
Fu Rong,Lu Lin,Gong Fengying,et al.Molecular mechanisms of Cushing’s disease and targeted drug[J].International Journal of Endocrinology and Metabolism,2016,36(02):400.[doi:10.3760/cma.j.issn.1673-4157.2016.06.11]
[2]倪文婧,徐书杭,刘超.2021年美国甲状腺学会关于甲状腺未分化癌管理指南解读:实践精准医学[J].国际内分泌代谢杂志,2022,42(02):161.[doi:10.3760/cma.j.cn121383-20211101-11002]
Ni Wenjing,Xu Shuhang,Liu Chao..Interpretation of 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: era of individualized precision medicine[J].International Journal of Endocrinology and Metabolism,2022,42(02):161.[doi:10.3760/cma.j.cn121383-20211101-11002]
[3]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(02):216.[doi:10.3760/cma.j.cn121383-20220307-03015]